Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells

Fukuda, Kazunori; Hibiya, Yuko; Mutoh, Michihiro; Koshiji, Masatoshi; Akao, Seigou; Fujiwara, Hisayoshi

doi:10.1016/s0378-8741(98)00162-7

Cited by 228 publications

(123 citation statements)

References 18 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…The reduction of liver lipids is beneficial to liver function by restoring hepatocyte morphology and reduction of liver steatosis [26]. Published data indicated that BBR and PS, when administered alone, have beneficial effects on the immune function [62][63][64][65][66]. As it was not measured in the current study, it is not clear whether reduced spleen weight by the combined treatment of BBRPS influences the immune function.…”

Section: Discussionmentioning

confidence: 65%

Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats

Xiao-ming¹,

Chen

Zidichouski³

et al. 2008

Atherosclerosis

View full text Add to dashboard Cite

The objective of the present study was to determine the beneficial effects and the safety of oral administration of the combination of berberine (BBR) and plant stanols (PS) on plasma lipid profiles in male Sprague-Dawley rats. Four groups of animals were fed a cornstarch-casein-sucrose-based high-cholesterol (2%, w:w) and high-fat (27.5%) diet. Three treatment groups were supplemented with either BBR (100 mg kg −1 body weight d −1 ), PS (1% in diet, w:w), or the combination of both (BBRPS). After 6 wk, animals were sacrificed and followed immediately with the collection of blood and organ samples. Lipid analysis revealed that PS lowered plasma total cholesterol (T-C) by 18% (p = 0.067) and non-HDL-cholesterol (non-HDL-C) by 29% (p = 0.013) as compared with the control, while BBR had no effect on both T-C and non-HDL-C. The combination treatment of BBRPS reduced plasma T-C by 41% (p = 0.0002) and non-HDL-C by 59% (p < 0.0001) compared to the control group. BBR reduced plasma TG levels by 31% at a marginal significance relative to the control (p = 0.054), whereas PS had no effect. BBRPS showed an additive effect of BBR and PS on plasma TAG. PS and BBRPS both decreased liver cholesterol (p = 0.0027 and 0.0002, respectively). BBR and PS, either alone or in combination, did not show any toxic effects as assessed by plasma concentration of hepatic biochemical parameters. These results demonstrate that BBR and PS, when combined, synergistically lower plasma cholesterol levels and significantly reduce liver cholesterol, without the observation of any toxic effects. Crown

show abstract

Section: Discussionmentioning

confidence: 65%

Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats

Xiao-ming¹,

Chen

Zidichouski³

et al. 2008

Atherosclerosis

View full text Add to dashboard Cite

show abstract

“…Berberine has tremendous potential to cure many physiological disorders; hence, it has been used in the Ayurvedic [6], Unani, and Chinese as well as Homeopathic medicine. Berberine has been shown to inhibit activator protein 1, a key transcription factor in inflammation and carcinogenesis, in human cell lines [7] and has been shown to possess antitumor properties and effectively inhibit cyclooxygenase-2 transcriptional activity in human colon cancer cells [8,9]. Berberine is known to inhibit DNA topoisomerase II [10].…”

Section: Introductionmentioning

confidence: 99%

Encapsulation of Berberine in Nano-Sized PLGA Synthesized by Emulsification Method

Khemani¹,

Sharon²,

Sharon³

2012

ISRN Nanotechnology

View full text Add to dashboard Cite

Nanoparticles of PLGA (polylactide glycolic acid) were prepared using biodegradable poly (D, L-lactide-co-glycolide)-75 : 25, by emulsification method using PVA (Mol. Wt. 9000) or didodecyl dimethyl ammonium bromide (DMAB) as surfactant. Nanoparticles were morphologically characterized using scanning electron microscope (SEM) and particle size analyzer. The distribution of size of PLGA nanoparticles was in the range of 48-211 nm. Berberine, a yellow isoquinoline alkaloid that is used as traditional anticancer drug, was loaded on to PLGA nanoparticles by single emulsion as well as multiple emulsion solvent evaporation techniques. Particle size analysis showed an increase in berberine loaded PLGA NP size to 180-310 nm when PVA was used as a stabilizer. Whereas use of DMAB as a stabilizer led to precipitation. In vitro drug release analysis revealed that acidic pH of 5.5 was more suitable for release of berberine than pH 7.4.

show abstract

“…Berberine has been shown to possess antiinflammatory activities in vivo (11) and preliminary studies have been conducted to determine its anticarcinogenic activity in skin (12). It has been shown to inhibit activator protein 1, a key transcription factor in inflammation and carcinogenesis, in human cell lines (13) and has been shown to possess antitumor properties and effectively inhibit cyclooxygenase-2 transcriptional activity in human colon cancer cells (14,15). Berberine has been shown to inhibit DNA topoisomerase II (16), and in fact, several classes of compounds that inhibit eukaryotic topoisomerase I or II have antitumor activity (17).…”

Section: Introductionmentioning

confidence: 99%

Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells

Mantena¹,

Sharma²,

Katiyar

2006

Molecular Cancer Therapeutics

316

218

View full text Add to dashboard Cite

Berberine, a naturally occurring isoquinoline alkaloid, has been shown to possess anti-inflammatory and antitumor properties in some in vitro systems. Here, we report that in vitro treatment of androgen-insensitive (DU145 and PC-3) and androgen-sensitive (LNCaP) prostate cancer cells with berberine inhibited cell proliferation and induced cell death in a dose-dependent (10 -100 Mmol/L) and timedependent (24 -72 hours) manner. Treatment of nonneoplastic human prostate epithelial cells (PWR-1E) with berberine under identical conditions did not significantly affect their viability. The berberine-induced inhibition of proliferation of DU145, PC-3, and LNCaP cells was associated with G 1 -phase arrest, which in DU145 cells was associated with inhibition of expression of cyclins D1, D2, and E and cyclin-dependent kinase (Cdk) 2, Cdk4, and Cdk6 proteins, increased expression of the Cdk inhibitory proteins (Cip1/p21 and Kip1/p27), and enhanced binding of Cdk inhibitors to Cdk. Berberine also significantly (P < 0.05 -0.001) enhanced apoptosis of DU145 and LNCaP cells with induction of a higher ratio of Bax/Bcl-2 proteins, disruption of mitochondrial membrane potential, and activation of caspase-9, caspase-3, and poly(ADP-ribose) polymerase. Pretreatment with the pan-caspase inhibitor z-VAD-fmk partially, but significantly, blocked the berberineinduced apoptosis, as also confirmed by the comet assay analysis of DNA fragmentation, suggesting that berberineinduced apoptosis of human prostate cancer cells is mediated primarily through the caspase-dependent pathway. The effectiveness of berberine in checking the growth of androgen-insensitive, as well as androgensensitive, prostate cancer cells without affecting the growth of normal prostate epithelial cells indicates that it may be a promising candidate for prostate cancer therapy.

show abstract

Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells

Cited by 228 publications

References 18 publications

Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats

Co-administration of berberine and plant stanols synergistically reduces plasma cholesterol in rats

Encapsulation of Berberine in Nano-Sized PLGA Synthesized by Emulsification Method

Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells

Contact Info

Product

Resources

About